Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

$33.3 million in cash and cash equivalents as of June 30, 2023; runway through August 2024
CRANFORD, N.J., Aug. 14, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. , a late-stage...

Related Keywords

New Jersey ,United States ,Greg Salsburg ,Leonard Mazur ,Ilanit Allen ,Jersey Technology Business Tax Certificate Transfer Program ,Exchange Commission ,Citius Pharmaceuticals Inc ,Securities Exchange ,Development Rd Expenses ,Prnewswire Citius Pharmaceuticals Inc ,Company Nasdaq ,Chief Executive Officer ,Halo Lido Phase ,Citius Pharmaceuticals ,Fast Track ,Securities Act ,Securities Exchange Act ,Annual Report ,Tables Follow ,Loss Per Share ,Flows From Operating Activities ,Flows From Financing Activities ,Cash Equivalents ,